A Phase I/II Study of MORAb-202 in People with Endometrial or Ovarian Cancer


Full Title

A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FR¿)-Targeting Antibody-Drug Conjugate (ADC) in Subjects With Selected Tumor Types


The purpose of this study is to assess the safety and effectiveness of the investigational drug MORAb-202 in people with endometrial or ovarian cancer. MORAb-202 targets a protein called FRA on cancer cells and delivers eribulin (a chemotherapy drug) directly to these cells, which may slow or stop cancer growth. MORAb-202 is given intravenously (by vein).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have advanced, recurrent, or metastatic endometrial or ovarian cancer that continues to grow despite prior platinum-based chemotherapy or immunotherapy.
  • At least 3 weeks must pass since the completion of previous treatment and receipt of MORAb-202.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for women age 18 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Vicky Makker at 646-888-4224.




Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID